This report was first published by Endpoints News. To see the original version, click here
Pfizer has won the bidding war for the obesity drug developer Metsera. The biotech accepted an increased bid from the New York pharma worth a total of $10 billion.
Late Friday night, Metsera said it had opted for Pfizer over the Danish drugmaker Novo Nordisk, which launched an unsolicited bid on Oct. 30. Pfizer and Metsera had initially agreed on a takeover deal worth a total of $7.3 billion on Sept. 22.
您已阅读40%（496字），剩余60%（754字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。